痰热清对慢性阻塞性肺疾病急性加重期患者降钙素原和T淋巴细胞亚群的影响

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (554 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Tanreqing on procalcitonin (PCT) and T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 100 patients with acute exacerbation of COPD who were treated in the Department of Internal Medicine, Jiangxi Chest Hospital from January 2017 to December 2019 were selected as the research subjects, they were divided into an observation group and a control group by random number table method, 50 cases in each group. The patients in the control group received conventional treatments such as oxygen inhalation, bronchodilators and anti-infection, patients in the observation group were treated with Tanreqing Injection on the basis of the control group. Both groups continued treatment for one week.The immune function, peripheral blood PCT and C-reactive protein (CRP) levels were compared between the two groups before and after treatment. Results There were no statistically significances in the levels of PCT, CRP, CD4+/CD8+, CD4+and CD8+ in the peripheral blood of the patients in the two groups before treatment (P＞0.05). The levels of CD4+/CD8+ and CD4+ in the peripheral blood of the patients in the two groups after treatment were higher than those before, the levels of CD4+/CD8+ and CD4+ in the peripheral blood of the patients in the observation group were higher than those of the control group, and the differences were statistically significant (P＜0.05). The levels of CD8+, PCT and CRP levels in the peripheral blood of the patients in the two groups after treatment were lower than those before treatment, the levels of CD8+, PCT and CRP levels in the peripheral blood of the patients in the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05). Conclusion Tanreqing can improve the immune function of patients with acute exacerbation of COPD, reduce the inflammatory response, and relieve patients′ symptoms.

Key words： Acute exacerbation of chronic obstructive pulmonary disease Tanreqing Procalcitonin C-reactive protein T lymphocyte subsets

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Lizhen
	XIONG Jiangqin
	YU Jia

Cite this article:

FAN Lizhen,XIONG Jiangqin,YU Jia. Effect of Tanreqing on procalcitonin and T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. 中国当代医药, 2022, 29(2): 48-51.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I2/48

[16]	任兴帅.痰热清注射液治疗慢性阻塞性肺疾病急性加重期患者的临床疗效与机制分析[J].中国实用医药，2021，16（4）：7-10.
[1]	谢嘉嘉，周继红，张立.健脾温肾汤辅助治疗慢性阻塞性肺疾病急性加重期临床分析[J].实用中医药杂志，2021，37（2）：239-240.
[2]	林亚辉.布地奈德福莫特罗吸入剂联合复方丹参滴丸治疗慢性阻塞性肺疾病稳定期的疗效分析[J].中国处方药，2021，19（2）：95-96.
[3]	崔建建.吸入糖皮质激素联合支气管舒张剂治疗慢性阻塞性肺疾病的临床价值分析[J].吉林医学，2021，42（3）：679-680.
[4]	徐伟俊，孙潇君，丁明罡，等.痰热清注射液雾化吸入佐治慢性阻塞性肺疾病急性加重期疗效观察[J].中国中医急症，2017，26（5）：162-164.
[5]	中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.慢性阻塞性肺疾病基层诊疗指南（实践版·2018）[J].中华全科医师杂志，2018，17（11）：871-877.
[6]	李建生，李素云，余学庆.慢性阻塞性肺疾病中医诊疗指南（2011 版）[J].中医杂志，2012，53（1）：80-84.
[7]	王志光.痰热清注射液联合西药治疗对慢性阻塞性肺疾病患者肺功能和细胞因子的影响[J].河南医学研究，2020，29（18）：3392-3393.
[8]	李宁宁，甘文云，刘辉.慢性阻塞性肺疾病患者血清神经生长素受体的表达水平及其与慢性阻塞性肺疾病评估测试评分、BODE 指数的相关性[J].临床内科杂志，2021，38（2）：109-112.
[9]	李霞.头孢噻肟钠联合地塞米松治疗肺部感染的临床效果及对炎症反应发生的影响[J].中国药物与临床，2021，21（3）：430-432.
[10]	王一萍.玉屏风颗粒辅助噻托溴铵治疗稳定期慢性阻塞性肺疾病临床观察及对肺功能的影响[J].新中医，2021，53（3）：31-34.
[11]	付群.血清免疫炎症因子及肺小动脉结构变化与肺动脉压的关系[J].中国临床医生杂志，2021，49（3）：299-302.
[12]	王亮，陶玉龙，陈万生.痰热清注射液化学成分、药理作用及临床应用研究进展[J].中草药，2020，51（12）：3318-3328.
[13]	俞洋，欧阳洋，杨晓龙.痰热清治疗对AECOPD 患者症状、血气、肺功能指标及炎性因子水平的影响[J].现代生物医学进展，2020，20（5）：897-900.
[14]	张莉，马铭，张王锋.沙美特罗替卡松联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].药物评价研究，2021，44（3）：577-581.
[15]	丁晓彦，林志军，王岱.金银花-连翘药对的成分和药理作用研究进展[J].山东科学，2019，32（3）：36-41.